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A B S T R A C T
Tuberculosis (TB) today remains a global emergency affecting 9.0 million people globally. The African
Region bears the highest global TB/HIV burden and over 50% of TB cases in SSA are co-infected with HIV.
An estimated 1.5 million died from the TB globally in 2013. A large majority of the 360,000 HIV-positive
TB cases who died were from sub-Saharan Africa. Research and development is an important pillar of the
WHO post-2015 global TB strategy. Advances in development of diagnostics, drugs, host-directed
therapies, and vaccines will require evaluation under ﬁeld conditions through multi-centre clinical trials
at different geographical locations. Thus it is critically important that these evaluations are fully
supported by all African governments and the capacity, trained staff and infrastructure required to
perform the research and evaluations is built and made available. This viewpoint article reviews the
opportunities provided by recently launched second programme (2015-2024) of the European &
Developing Countries Clinical Trials Partnership (EDCTP2) for tackling the TB epidemic in Africa through
its magnanimous portfolio. The unique opportunities provided by EDCTP2 for leadership of scientiﬁc
research in TB and other diseases fully devolving to Africa are also covered.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idTuberculosis (TB) and HIV/AIDS remain two of the most
common causes of death from an infectious disease
worldwide1. The latest 2014 WHO annual Global TB report
estimates that in 2013, there were 9.0 million people (3.3 million
women and 500,000 children) who developed TB2 of which an
estimated 1.2 million TB cases (14%) were in people living with
HIV. TB imposes a huge burden on the already overstretched health
services in sub-Saharan Africa (SSA). Although SSA has 12% of the
world’s population it generated 29% of the 9 million TB cases and
had 254,000 TB related deaths. SSA bears the highest global TB/HIV
burden and over 50% of TB cases in SSA are co-infected with
HIV2. An estimated 1.5 million died from TB globally in 2013, of
which a large majority of the 360,000 HIV-positive TB cases who
died were from sub-Saharan Africa.
The current WHO estimates on the global burden of TB2 may
represent an underestimate of the actual burden since they are* Corresponding author. Kenya Medical Research Institute, Nairobi, Kenya.
E-mail address: chakaya.jm@gmail.com (J. Chakaya).
http://dx.doi.org/10.1016/j.ijid.2014.12.039
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).based mainly on calculations from reported TB case notiﬁcation
data and expert opinion about accuracy of reporting. In Africa the
actual magnitude of the TB problem remains undeﬁned due to poor
laboratory and diagnostics infrastructures, case detection, record-
ing and reporting systems. According to the WHO Report2 the ﬁrst-
ever national survey of the prevalence of TB disease in Nigeria was
conducted in 2012 to estimate the prevalence of pulmonary TB
among the general adult population. The data from it resulted in a
substantial upward revision to WHO estimates of the country’s TB
disease burden by 200% higher for incidence, 100% higher for
prevalence and 400% higher for mortality2. Thus numbers of TB
cases in SSA need to be deﬁned more accurately since apart from
identiﬁcation of TB cases, there appears to be a large undiagnosed
and sub-clinical load of TB as recently shown by studies in the
inpatient paediatric3, adult4 and obstetrics wards5, at the
University Teaching Hospital in Lusaka, Zambia, and from autopsy
studies from Africa6.
An ominous increase is being seen globally in the number of
new cases of Multi-Drug Resistant TB (MDR-TB)7,8, caused byciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Table 1
Components of the STOP TB Strategy (2)
1. Pursue high-quality DOTS expansion and enhancement
a. Secure political commitment, with adequate and sustained ﬁnancing
b. Ensure early case detection, and diagnosis through quality-assured
bacteriology
c. Provide standardized treatment with supervision, and patient support
d. Ensure effective drug supply and management
e. Monitor and evaluate performance and impact
2. Address TB/HIV, MDR-TB, and the needs of poor and vulnerable
populations
a. Scale up collaborative TB/HIV activities
b. Scale up prevention and management of MDR-TB
c. Address the needs of TB contacts, and of poor and vulnerable populations
3. Contribute to health system strengthening based on primary health
care
a. Help improve health policies, human resource development, ﬁnancing,
supplies, service delivery and information
b. Strengthen infection control in health services, other congregate settings
and households
c. Upgrade laboratory networks, and implement the Practical Approach to
Lung Health
d. Adapt successful approaches from other ﬁelds and sectors, and foster
action on the social determinants of health
4. Engage all care providers
a. Involve all public, voluntary, corporate and private providers through
public–private mix approaches
b. Promote use of the International Standards for Tuberculosis Care
5. Empower people with TB, and communities through partnership
a. Pursue advocacy, communication and social mobilization
b. Foster community participation in TB care, prevention and health
promotion
c. Promote use of the Patients’ Charter for Tuberculosis Care
6. Enable and promote research
a. Conduct programme-based operational research
b. Advocate for and participate in research to develop new diagnostics, drugs
and vaccines
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rifampicin and isoniazid, and of Extensively Drug-Resistant TB
(XDR-TB), (resistance to rifampicin, isoniazid, plus any ﬂuoroquin-
olone and at least one of the three injectable second line TB drugs:
amikacin, kanamycin, capreomycin). There were an estimated
480,000 new cases of MDR-TB globally in 20132. These ﬁgures too
are likely to be underestimated, especially in Africa due to a
widespread lack of laboratory infrastructure and resources for
drug-resistance testing. Molecular technologies such as Geno-
Type1 MTBDRplus (Hain Lifescience, Germany), Xpert1 MTB/RIF
(Cepheid, USA) are increasingly being incorporated into drug
resistance surveys and laboratory services globally, including
several SSA countries9, and thus it is likely that MDR-TB numbers
will be revised upward. Worryingly, the success rate of MDR-TB
treatment was only 48% worldwide2. Weaknesses in health
systems, lack of resources and ineffective treatment regimens
coupled with other operational treatment challenges all contribute
to the low cure rates.
The Global Plan to Stop TB 2011–201510 set several targets11
(Table 1) to curtail the co-epidemics of TB and HIV and the
epidemic of MDR-TB. Key targets were that 100% of TB patients
should know their HIV status, 100% of HIV-positive TB patients
should receive antiretroviral therapy and that newly enrolled
patients in HIV care programs with latent TB infection should
receive preventive TB therapy with isoniazid. The main 2015 tar-
gets for MDR-TB were that all MDR-TB patients should be detected
and treated with second-line TB treatment regimens, and the
success rate should be 75%. To date none of these targets have
been achieved in SSA2.
Research and development is an important pillar of the WHO
post-2015 global TB strategy11. The overall goal of the strategy is to
end the global TB epidemic, with 2035 targets of a 95% reduction in
TB deaths and a 90% reduction in TB incidence compared to
2015. Operational research should remain a priority12,13 and waysto improve optimal delivery of TB and HIV health services, gaining
patient conﬁdence, acceptance and adherence to TB care and
ﬁnding the missing 3 million cases of TB14 must be found. New
research and development into new diagnostic tests, new TB drugs,
new treatment regimens which shorten duration of therapy, new
regimens for MDR-TB, adjunct treatments, and new TB vaccines
may play an important future role in achieving post-2015 global TB
targets if any of them will prove to be of practical use for TB
management at points of care. Whilst we await major scientiﬁc
breakthroughs from the current research portfolio, it is of critical
importance to note that there are important socio-economic
factors coupled with poor housing and health services12 that are
main drivers of the global TB epidemic15. Unless these are seriously
addressed by the global community and corrected, global TB
control will be difﬁcult to achieve and will take a long time.
Meanwhile the huge TB load can be reduced signiﬁcantly using
currently available diagnostic tools and drug regimens if they are
used and delivered optimally.
Several new TB diagnostics have become available over the past
5 years and some have undergone rapid evaluations in numerous
studies16. Two new TB drugs, Bedaquiline and Delamanid, have
emerged from the TB drug pipeline17 and are being evaluated in
several combinations in trials using adaptive designed for drug
sensitive and drug resistant TB and reducing duration of
therapy18. There are up to 15 TB candidate vaccines being
developed and several are undergoing phase 1, 2 and
3 evaluation19. All these new tools and interventions will need
careful evaluation under ﬁeld conditions in multi-centre clinical
trials at different geographical locations. All new interventions and
tools which show promise from initial evaluations should be
viewed with cautious optimism as experience with the two
Gamma interferon assays20 and the GeneXpert MTB/RIF Assay21
has shown. Both tests were rapidly and vigorously promoted due
to the assumption they would revolutionize the TB diagnostic and
management landscape. New technologies always perform well
under controlled trial situations, and it is essential that they are
evaluated under operational ﬁeld conditions within health
systems. The Xpert MTB/RIF Assay was seen and promoted as a
game-changer in the TB diagnostic landscape but concerns remain
with respect to implementation challenges for the lower levels of
the health system, applicability as a point of care test, use in
different epidemiological settings, advantage over time to
treatment, effect on treatment outcome, and cost2. Furthermore
new data which is generated without close engagement of local
scientists, clinicians, end users and policy makers may hinder the
implementation of research ﬁndings and recommendations into
policy and practice. More importantly, individual research projects
with limited grant funding, and dominance of basic science and
clinical trials research in Africa by researchers from western
country institutions22 does not lead to effective development of
local capacity, infrastructure and goodwill for research and
infrastructure to be sustained long term.
Initial clinical trials of TB drugs and treatment regimens
including short course chemotherapy were conducted in Africa in
the 1950s by the UK Medical Research Council23, Since then there
has been a dominance of ensuing TB clinical and epidemiological
research activities in Africa by western countries with little
involvement of African scientists22. As African countries gained
independence and local universities were built, African scientists
became increasingly empowered to take on the challenges of
research on local health problems. The ‘annexed site’ and
‘parachute research’ colonial models of research which operated
in Africa in the 20th century were challenged22 and African scientist
led initiatives were initiated, which were successful in developing
more equitable research and capacity development south-north
partnerships24. The past two decades have seen a renaissance of
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throughout SSA focused on malaria, HIV/AIDS, TB, parasitic
infections and co-morbidities of communicable diseases with
non-communicable diseases.
The establishment in 2003 of The European & Developing
countries Clinical Trials Partnership (EDCTP),25,26 by the European
Parliament and of the Council of the European Union was a major
boost to these efforts for developing and sustaining local research,
training and capacity development27–30. When the EDCTP was ﬁrst
launched in 2003 it was a partnership between 16 European
countries, European Union and sub-Saharan Africa. EDCTP’s remit
was to facilitate the progress of promising new technologies and
products through the pipeline; conduct the necessary evaluation
clinical trials in Africa; support ethics and regulatory components
and promote collaboration with industry, product developers,
other research funders and development cooperation agencies, and
catalyze innovation toward the development of new or improved
drugs, vaccines, microbicides and diagnostics for TB, HIV/AIDS and
malaria. Despite pessimistic predications by armchair critics31,32
the mission and objectives of the EDCTP to become a game changer
was applauded by African scientists24. Subsequently EDCTP
successes and investments over the past decade may have
surpassed that of any other scientiﬁc and capacity development
funding agency or initiative in Africa27–33.
The TB-speciﬁc investments by EDCTP have focused on
development of new TB diagnostics, drugs and vaccines and
applications of existing diagnostic tools to expand clinical trials
infrastructure in SSA33. EDCTP support has led to development of
clinical trial partnerships between European and other interna-
tional organizations with sub-Saharan African countries and
mobilization of resources for establishment of clinical trials
infrastructure including appropriate laboratory infrastructure.
These sites are now being used for evaluation of several new TB
diagnostics, TB drugs and drug regimens, and TB vaccines. The
EDCTP-funded Pan African Consortium for the Evaluation of
Antituberculosis Antibiotics (PanACEA)34 consists of nine Europe-
an universities and 11 African clinical trial centres. This consortium
is evaluating several new TB drugs and TB treatment regimens. The
Rapid Evaluation of Moxiﬂoxacin in Tuberculosis (REMoxTB)
trial35 was the ﬁrst regulatory phase III clinical trial of a
treatment-shortening regimen. The RIFAQUIN Trial36 compared
regimens that included weekly administration of high-dose
rifapentine and moxiﬂoxacin. Both trials showed that moxiﬂox-
acin-containing regimens were not effective in the African setting
for shortening therapy to 4 months. Several EDCTP funded
evaluations of new TB diagnostics showed that GeneXpert MTB/
RIF Assay is useful in SSA settings to simplify patients’ access to
early and accurate diagnosis and that it could be used as the initial
diagnostic test in individuals suspected of MDR-TB or HIV-
associated TB21 and for more rapid proactive screening for sub-
clinical TB and in paediatric, obstetrics and adult inpatient wards at
tertiary care hospitals3–5. An EDCTP-funded a trial of MVA85
vaccine in HIV-infected adults in South Africa and Senegal is
ongoing33.
The ﬁrst programme of EDCTP ended in 2014. It made notable
and signiﬁcant investments in TB research and contributed to the
establishment of state-of-the-art clinical and diagnostic laboratory
infrastructure and training of a range of scientists and health
personnel expediting TB related research33. So successful was the
ﬁrst EDCTP programme that on December 2nd 2014 there was a
historic launch of the second programme (EDCTP2) in Cape Town
under the auspices of the European Commission and the South
African Department of Science and Technology37. EDCTP2 has
changed its legal structure from a European Economic Interest
Grouping to an Association under Dutch law enabling sub-Saharan
African countries to also become full members of EDCTP38. Thisarrangement reﬂects EDCTP’s commitment to equal partnership
built on joint ownership, leadership and trust with mutual beneﬁt.
Current EDCTP2 membership of the EDCTP Association now
includes 13 European countries (Austria, Denmark, Finland, France,
Germany, Ireland, Italy, Luxembourg, The Netherlands, Norway,
Portugal, Spain, and United Kingdom) and 13 African countries
(Cameroon, Republic of the Congo, The Gambia, Ghana, Mozambi-
que, Niger, Senegal, South Africa, Tanzania, Uganda, Mali, Burkina
Faso and Zambia).
EDCTP2 provides unique and extraordinary opportunities for
facilitating and enhancing TB control efforts in SSA. By pooling
resources, EDCTP increases coordination of national and regional
research programs and reduces fragmentation and duplication.
EDCTP2 investments will generate mutually beneﬁcial collabora-
tions among south-north institutions, simultaneously building
capacity for conduct of large, multinational projects. Such an
approach would enable large research projects that cannot be
addressed by a single group and serve the large international
footprint characteristic of such endeavors. With African govern-
ments as equal partners, close engagement of end-user communi-
ties and policy makers will allow national priorities for research to
be taken forward and the results of research be translated into
policy and practice. EDCTP2 will allow a cohesive program of
multidisciplinary research to be undertaken to address some of the
key questions that could impact on lowering the burden of TB
disease in Africa and worldwide. This will also include high quality
research that provides a step up change in our understanding of the
optimization of health systems to deliver new or existing evidence-
based interventions for the beneﬁt of the peoples of Africa and
beyond. EDCTP2 will also allow stimulation of dialogue about
biomedical research and its impact on the public in a range of
community and industry contexts; promote innovative partner-
ships between end users, community organizations and the
cultural sector, and strengthen capacity to conduct public
engagement with biomedical science and health research.
It is also anticipated that EDCTP2 partnerships and investments
will lead to establishment and consolidation of an SSA wide resource
of collaborating TB and TB/HIV centers, networks and expertise
which will foster collaborations, stimulate, and expand basic,
translational clinical and applied research, advancing scientiﬁc
discovery. It is anticipated that more African research leaders will
emerge and will lead independent self-perpetuating, African
investigator-driven, long-lasting south-north research and training
partnerships designed to address issues of local importance,
coordinated through the utilization of common standards and
practices. This will also ensure that research focusses on regional or
national or continental relevant research questions, the answers to
which will serve national and regional public health needs and
priorities. This will no doubt enhance further development of novel
health technologies, novel compounds and drugs from local
resources and support multinational multi-disciplinary projects that
combine clinical trials, capacity building and networking activities in
partnership with European and other countries. The capacity built
will also assist in regional and continental public health response to
novel and emerging new infectious diseases threats39.
The overarching goal of the post-2015 WHO TB strategy is to
end the global TB epidemic by 2035, with corresponding global
targets for a 95% reduction in the number of TB deaths and a 90%
reduction in the number of cases by 2035, compared with a
baseline of 2015. Milestones for 2020, 2025 and 2030 are also
included and that by 2020 no TB patients or their households
experience catastrophic costs as a result of their disease. Achieving
the proposed targets is based on three strategic pillars: integrated,
patient-centered care and prevention; bold policies and supportive
systems; and intensiﬁed research and innovation. As more African
researchers take on leadership positions, it has become important
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capacity building investments in Africa40,41 with EDCTP to have a
synergistic and multiplier effect. It is only through empowerment of
the next generation of scientiﬁc leaders who will conduct the highest
level of research that Africa will be able to generate local solutions to
local health issues. The case in point here is that solutions for Africa’s
TB problem should arise from African leadership of scientiﬁc
research, fully engaged in redressing and resurrecting the imbal-
ances underpinning scientiﬁc leadership and bringing equitable
relationships with European scientists. ‘Holding hands together and
moving forward in the ﬁght against killer infectious diseases’ is the
only way forward to achieve MDG targets. EDCTP2 investments into
development of research and capacity in Africa through equitable
north-south partnerships far surpasses that of any other41 and its
laudable portfolio provides unique opportunities of leadership of
scientiﬁc work fully devolving to Africa in TB/HIV and allow post-
2015 TB targets to be achieved in SSA.
Author declarations: AZ serves on the Strategic Advisory
Committee of the EDCTP. TN is EDCTP South-South Networking
and Capacity Development Manager and TB focal person. All other
authors declare no conﬂicts of interests.
References
1. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global,
regional, and national incidence and mortality for HIV, tuberculosis, and
malaria during 1990–2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet 2014 Sep 13;384(9947):1005–70.
2. World Health Organisation Global Tuberculosis report 2014. http://www.who.
int/tb/publications/global_report/en/ -accessed November 29th, 2014. WHO/
HTM/TB/2014.
3. Bates M, O’Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, et al. Assess-
ment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric
lavage aspirates in children in sub-Saharan Africa: a prospective descriptive
study. Lancet Infectious Diseases 2013;13(1):36–42.
4. Bates M, O’Grady J, Mwaba P, Chilukutu L, Mzyece J, Cheelo B, et al. Evaluation of
the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-
communicable diseases in sputum producing adult inpatients. PLoS One
2012;7(7):e40774. doi: 10.137.
5. Bates M, Ahmed Y, Chilukutu L, Tembo J, Cheelo B, Sinyangwe S, et al. Use of the
Xpert((R)) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity
and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at
the University Teaching Hospital, Lusaka, Zambia. Trop Med Int Health
2013;18(9):1134–40.
6. Mudenda V, Lucas S, Shibemba A, O’Grady J, Bates M, Kapata N, et al. Tubercu-
losis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need
to expand and invest in routine and research autopsies. J Infect Dis 2012 May
15;205(Suppl 2):S340–6.
7. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, et al. Drug-resistant
tuberculosis: time for visionary political leadership. Lancet Infect Dis
2013 Jun;13(6):529–39.
8. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD,
et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions,
challenges, and priority needs. J Infect Dis 2012 May 15;205(Suppl 2):
S228–40.
9. Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, et al.
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a
framework for action. Lancet Infect Dis 2013;13(5):449–58.
10. Report: The Global plan to stop TB 2011–2015. http://www.stoptb.org/assets/
documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf -accessed De-
cember 12th 2014.
11. WHO Report: Global strategy and targets for tuberculosis prevention, care and
control after 2015. http://apps.who.int/gb/ebwha/pdf_ﬁles/EB134/B134_
12-en.pdf?ua=1 29 November 2013 -accessed December 12th 2014.
12. Zumla A, Cobelens F. Operational research and MDG tuberculosis control
targets. Lancet Infect Dis 2012;12(4):262–3.
13. Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A. A sustainable agenda
for tuberculosis control and research. Lancet 2012;379(9821):1077–8.14. Herbert N, George A. Baroness Masham of I, Sharma V, Oliver M, Oxley A,
Raviglione M, Zumla AI. World TB Day 2014: ﬁnding the missing 3 million.
Lancet 2014;383(9922):1016–8.
15. Grange JM, Zumla A. The global emergency of tuberculosis: what is the cause? J
R Soc Promot Health 2002 Jun;122(2):78–81.
16. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ. Advances in
tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a
point-of-care test. Lancet Infect Dis 2013;13(4):349–61.
17. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, et al. New antituber-
culosis drugs, regimens, and adjunct therapies: needs, advances, and future
prospects. Lancet Infect Dis 2014 Apr;14(4):327–40.
18. Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, et al.
Innovative trial designs are practical solutions for improving the treatment of
tuberculosis. J Infect Dis 2012 May 15;205(Suppl 2):S250–7. http://dx.doi.org/
10.1093/infdis/jis041. Epub 2012 Mar 22.
19. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in
tuberculosis vaccine development and host-directed therapies-a state of the art
review. The Lancet Respiratory Medicine 2014;2(4):301–20.
20. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB. Interferon-g release
assays for the diagnosis of active tuberculosis: a systematic review and meta-
analysis. Eur Respir J 2011 Jan;37(1):100–11.
21. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al., TB-NEAT
team. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF
testing for tuberculosis in primary-care settings in Africa: a multicentre,
randomised, controlled trial. Lancet 2014 Feb 1;383(9915):424–35.
22. Costello A, Zumla A. Moving to research partnerships in developing countries.
BMJ 2000 Sep 30;321(7264):827–9.
23. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis:
a Medical Research Council investigation. BMJ 1948;2:769–82.
24. Zumla A, Huggett J, Dheda K, Green C, Kapata N, Mwaba P. Trials and tribula-
tions of an African-led research and capacity development programme: the
case for EDCTP investments. Trop Med Int Health 2010;15:489–94.
25. ftp://ftp.cordis.europa.eu/pub/fp7/art169/docs/edctp.pdf Decision no 1209/
2003/ec of the European parliament and of the council of 16 June 2003-
accessed December 6, 2014. Ofﬁcial Journal of the European Union L169/1.
26. Olliaro P, Smith PG. The European and Developing countries clinical trials
partnership. J HIV Ther 2004;9:53–6.
27. Mgone C, Volmink J, Coles D, Makanga M, Jaffar S, Sewankambo N. Linking
research and development to strengthen health systems in Africa. Trop Med Int
Health 2010;15:1404–6.
28. Matee MI, Manyando C, Ndumbe PM, Corrah T, Jaoko WG, Kitua AY, et al.
European and Developing Countries Clinical Trials Partnership (EDCTP): the
path towards a true partnership. BMC Public Health 2009;9:249.
29. Mgone CS, Salami W. EDCTP: a genuine north-south partnership. Trop Med Int
Health 2009;14:1327–8.
30. Mgone CS, Makanga M. Fighting HIV/AIDS, tuberculosis and malaria: one world,
one partnership. Trop Med Int Health 2010;15:973–4.
31. Editorial: Europe’s science bureaucrats should learn from Gates success. Lancet
2005;366:2–3.
32. Editorial. Europe’s clinical trials partnership in peril. Lancet 2007:4 Aug.
374:362.
33. EDCTP Annual Report 2013: http://www.edctp.org/annualreport2013/
EDCTP_Annual_Report_2013_EN.pdf -Accessed October 16th, 2014.
34. PANACEA http://panacea-tb.net/ -accessed December 12th 2014.
35. Gillespie S, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray S, et al.
Four-month moxiﬂoxacin-based regimens for drug-sensitive tuberculosis. N
Engl J Med 2014;371:1577–87.
36. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S,
et al. High-dose rifapentine with moxiﬂoxacin for pulmonary tuberculosis. N
Engl J Med 2014;371:1599–608.
37. Zumla A, Makanga M, Nyirenda T, Beattie P, Olesen OF, Breugelmans JG, et al.
Genesis of EDCTP2. Lancet Infect Dis 2014 Dec 1. pii: S1473-3099(14)71034-5.
38. http://www.edctp.org/ﬁleadmin/documents/Towards_EDCTP_II/EDCTP2-
Decision556_2014_EU_2014-05-15.pdf. Decision No 556/2014/EU of the Euro-
pean Parliament and of Council of 15 May 2014 on the participation of the
Union in a second European and Developing Countries Clinical Trials Partner-
ship Programme (EDCTP2) jointly undertaken by several Member States. Ofﬁ-
cial Journal of the European Union L169/38. -accessed 16th October, 2014.
39. Al-Tawﬁq JA, Zumla A, Gautret P, Gray GC, Hui DS, Al-Rabeeah AA, et al.
Surveillance for emerging respiratory viruses. Lancet Infect Dis
2014 Oct;14(10):992–1000.
40. Mandala WL, Cowan FM, Lalloo DG, Wilkinson RJ, Kelly P, Chidzonga MM, et al.
Southern Africa Consortium for Research Excellence (SACORE): successes and
challenges. Lancet Glob Health 2014 Dec;2(12):e691–2. http://dx.doi.org/
10.1016/S2214-109X(14)70321-3.
41. 2014 Report on Tuberculosis Research Funding Trends’’ Treatment Action
Group, http://www.treatmentactiongroup.org/tbrd2014 accessed 12/11/2014.
